| P50 | author | Henrik Zetterberg | Q6252048 |
| P2860 | cites work | Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. | Q53417610 |
| | Plasma amyloid β-quo vadis? | Q53478803 |
| | Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases | Q58292492 |
| | Chemokines in CSF of Alzheimer's disease patients | Q59387647 |
| | Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone | Q61699068 |
| | Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD | Q73816529 |
| | Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice | Q81366189 |
| | Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease | Q82257191 |
| | TREM2 Variants in Alzheimer's Disease | Q22250873 |
| | Variant of TREM2 Associated with the Risk of Alzheimer's Disease | Q22250874 |
| | Amyloid plaque core protein in Alzheimer disease and Down syndrome | Q24568384 |
| | Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders | Q26741861 |
| | Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine | Q26768648 |
| | Neurodegenerative diseases: expanding the prion concept | Q27011744 |
| | Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies | Q27322513 |
| | Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation | Q27333145 |
| | Mammalian occludin in epithelial cells: its expression and subcellular distribution | Q28245297 |
| | Alzheimer's disease is a synaptic failure | Q29547670 |
| | Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration. | Q51657545 |
| | Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. | Q53274559 |
| | CSF biomarkers predict a more malignant outcome in Alzheimer disease. | Q53309901 |
| | Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. | Q53319037 |
| | Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. | Q53331697 |
| | Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. | Q53416640 |
| | Alzheimer's disease | Q29616743 |
| | Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology | Q29617284 |
| | Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 |
| | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria | Q30458193 |
| | DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease | Q30493811 |
| | Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. | Q33231194 |
| | Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease | Q33239536 |
| | Hyperphosphorylation of tau protein in superficial CNS siderosis | Q33350741 |
| | The neuropathology of probable Alzheimer disease and mild cognitive impairment | Q33616561 |
| | Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease | Q33822641 |
| | Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 |
| | YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease | Q34447497 |
| | Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy | Q34544824 |
| | SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease | Q34620335 |
| | National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease | Q34635272 |
| | Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia | Q34746995 |
| | The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease | Q35055373 |
| | TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices | Q35593790 |
| | Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls | Q35806251 |
| | sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers | Q35945633 |
| | A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes | Q36045119 |
| | CSF neurofilament proteins in the differential diagnosis of dementia | Q36227579 |
| | Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease | Q36276592 |
| | Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease | Q36402008 |
| | Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease | Q36412490 |
| | Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease | Q36454535 |
| | Increased CSF neurogranin concentration is specific to Alzheimer disease | Q36691986 |
| | Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease | Q36885492 |
| | Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status | Q36901561 |
| | Plasma β-amyloid in Alzheimer's disease and vascular disease | Q36949501 |
| | Plasma tau levels in Alzheimer's disease | Q36998625 |
| | Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology | Q37044150 |
| | Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile | Q37049024 |
| | Plasma tau in Alzheimer disease | Q37384690 |
| | Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies | Q37800101 |
| | Occludin: one protein, many forms | Q37956234 |
| | Alzheimer's disease: mimics and chameleons. | Q38059197 |
| | Amyloid biomarkers in Alzheimer's disease | Q38404428 |
| | Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease | Q38690632 |
| | TREM2 Function in Alzheimer's Disease and Neurodegeneration | Q38725942 |
| | Defeating Alzheimer's disease and other dementias: a priority for European science and society | Q38778638 |
| | CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis | Q38805517 |
| | Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia | Q38853776 |
| | CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation | Q38863280 |
| | Review: Tau in biofluids - relation to pathology, imaging and clinical features | Q39068040 |
| | Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease | Q39120758 |
| | TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia | Q39331146 |
| | Hydrodynamic Radii versus Molecular Weights in Clearance Studies of Urine and Cerebrospinal Fluid | Q39435703 |
| | CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival | Q39469698 |
| | Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly | Q39544835 |
| | α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study | Q39783457 |
| | Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions | Q39861856 |
| | Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. | Q40461425 |
| | APP metabolism regulates tau proteostasis in human cerebral cortex neurons | Q40660550 |
| | Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values | Q40833195 |
| | Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. | Q42057034 |
| | Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections | Q42271966 |
| | Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression | Q42287644 |
| | CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease | Q42742756 |
| | Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein | Q43861573 |
| | Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up | Q47958225 |
| | Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias | Q48010180 |
| | Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. | Q48016761 |
| | C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease | Q48119991 |
| | CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease | Q48162267 |
| | A New Panel of Blood Biomarkers for the Diagnosis of Mild Traumatic Brain Injury/Concussion in Adults | Q48270426 |
| | Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid | Q48405878 |
| | CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease | Q48408159 |
| | A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia | Q48480350 |
| | CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings | Q48559548 |
| | Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease | Q48665932 |
| | Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? | Q48819771 |
| | Blood brain barrier function in vascular dementia. | Q49026109 |
| | Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels | Q49093762 |
| | Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke | Q49117210 |
| | Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. | Q50221800 |
| | CSF tau protein is a useful marker for effective treatment of superficial siderosis of the central nervous system: two case reports. | Q50442677 |
| | Red blood cells are the major source of alpha-synuclein in blood. | Q50663283 |
| | Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. | Q50762201 |
| | Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. | Q50940972 |
| P433 | issue | 1 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| | biomarker | Q864574 |
| P304 | page(s) | C3-C10 | |
| P577 | publication date | 2017-04-19 | |
| P1433 | published in | American Journal of Physiology - Cell Physiology | Q2227080 |
| P1476 | title | Applying fluid biomarkers to Alzheimer's disease | |
| P478 | volume | 313 | |